SUSTIVA
LOE ApproachingNDAORALTABLET
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
SUSTIVA by Bristol Myers Squibb is [see clinical pharmacology ]. Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection. First approved in 2002.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTIVA is an oral small-molecule antiretroviral approved in 2002 for HIV infection and Hepatitis C treatment. The drug works as a non-nucleoside reverse transcriptase inhibitor to suppress viral replication in infected patients. It represents a foundational therapy class in HIV management with decades of clinical experience.
$25KPart D
LOE ApproachingDeclining
This product is in late-stage decline with minimal Part D utilization, signaling a shrinking commercial team and transition focus toward managed care and specialty channels.
Mechanism of Action
[see Clinical Pharmacology ].
Worked on SUSTIVA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.